

REMARKS

Claim 1 has been amended and claim 18 has been cancelled without prejudice or disclaimer. Claims 1, 19, 20, 22, 23, 30, and 35 are pending in the instant application. No new matter has been added as a result of the above-described amendments.

Applicants have amended the claims as proposed by the Examiner in a telephonic Interview with Applicants' undersigned representative on February 2, 2010 solely to expedite prosecution of the pending claims to allowance. Applicants reserve the right to pursue claims directed to trimeric polypeptides comprising (a) a portion of TNFRSF1A, TNFRSF1B, LTBR, TNFRSF4, TNFRSF5, TNFRSF6, TNFRSF6B, TNFRSF7, TNFRSF8, TNFRSF9, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFRSF11A, TNFRSF11 B, TNFRSF12, TNFRSF12L, TNFRSF13B, TNFRSF13C, TNFRSF14, NGFR, TNFRSF17, TNFRSF18, TNFRSF19, TNFRSF19L, TNFRSF21, TNFRSF22, or TNFRSF23 that binds a trimeric cytokine, and/or (b) comprising an amino acid sequence having less than 87% identity with the amino acid sequence of SEQ ID NO:81 in a timely filed continuation or divisional application, or alternatively, reintroduce such subject matter in the instant application at such time as the Office indicates that the pending claims are otherwise in condition for allowance.

Applicants respectfully contend that all conditions of patentability are met in the pending claims as amended. Allowance of the claims is thereby respectfully solicited.

Applicants do not believe that any additional fee is required for this Supplemental Amendment. However, the Commissioner is authorized to charge any deficiency to Deposit Account No. 13-2490.

If Examiner Mertz believes it to be helpful, she is invited to contact the undersigned representative by telephone at 312-913-0001.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff LLP

Dated: February 15, 2010

By: /Donald L. Zuhn, Jr./
Donald L. Zuhn, Jr., Ph.D.
Reg. No. 48,710